

IT'S WEDNESDAY, OCT 22 **10:02**

Your people's inboxes could be full of new insights by Friday.





GET THE FREE TRIAL

[Login](#) | [Register](#) | [Advertise](#) | [Contact](#)

Free Daily FiercePharma Newsletter: [About](#) | [Sample](#) | [Privacy](#)

Related Topics >> [Seroquel](#) | [AstraZeneca](#)

AZ bids for yet another Seroquel use

October 21, 2008 — 11:06am ET | By [Tracy Staton](#)

AstraZeneca is taking its [Seroquel-broadening mission](#) further into Europe with an application to market the atypical antipsychotic for generalized anxiety disorder. If European regulators approve the new use, Seroquel would be the first med in its class OK'd for anxiety.

The company says it's basing its application on five Phase III studies encompassing more than 3,500 patients. The data, presented at the American Psychiatric Association confab in May, showed "significantly greater symptom improvements" in the Seroquel patients versus those on placebo, the company said.

AstraZeneca is awaiting an FDA decision on using Seroquel to treat short-term anxiety and for long-term maintenance of the disorder. The company also has an application for major depressive disorder pending, both in the U.S. and in Europe.

- see the [AstraZeneca release](#)

Related Articles:

[AZ stock leaps on Seroquel hearing news](#)
[Seroquel researcher got cash from AZ](#)
[AZ takes steps to shore up Seroquel](#)
[AZ's Seroquel receives additional approval](#)

Be the first to comment

MORE STORIES ABOUT [Seroquel](#) [AstraZeneca](#)

Comments

Post new comment

Your name:

E-mail:

The content of this field is kept private and will not be shown publicly.

RELATED STORIES

[Abbott faces more AIDS suits](#)
[AZ stock leaps on Seroquel hearing news](#)
[U.K. kids' antipsychotic use doubled](#)
[Emerging markets drive global growth](#)
[Seroquel researcher got cash from AZ](#)

TOOLS

[Email](#)
[Print](#)
[Comment](#)
[Contact Author](#)

Comment: *

[More information about formatting options](#)

What is 8 + 7?

Answer: *

To combat spam, please solve the math question above.

Post comment

PAID RESEARCH REPORTS

[Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments](#)

[Drug Repositioning Strategies - Serendipity by design](#)

[eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process](#)

[Pricing & Reimbursement - Seven Major Markets Update](#)

[Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets](#)

[Home](#) | [Subscribe](#) | [Advertise](#) | [Mobile Edition](#) | [RSS](#) | [Privacy](#) | [Site Map](#)

THE FIERCEMARKETS NETWORK

[FierceFinance](#) | [FierceFinanceIT](#) | [FierceSarbox](#) | [FierceHealthcare](#) | [FierceHealthFinance](#) | [FierceHealthIT](#) | [Hospital Impact](#) | [FierceCIO](#) | [FierceCIO:TechWatch](#) | [FierceContentManagement](#) | [FierceMobileIT](#) | [FierceBiotech](#) | [FierceBioResearcher](#) | [FiercePharma](#) | [FierceVaccines](#) | [FierceIPTV](#) | [FierceOnlineVideo](#) | [FierceTelecom](#) | [FierceVoIP](#) | [FierceBroadbandWireless](#) | [FierceDeveloper](#) | [FierceMobileContent](#) | [FierceWireless](#) | [FierceWireless:Europe](#)

a publication of
FierceMarkets

© 2008 FierceMarkets, Inc. All rights reserved.